In response to the Office Action dated **March 25, 2003**, please amend the above-identified application as follows:

IN THE CLAIMS:

Cancel Claims 1, 2, 5, 6, 9, 10, 13 – 16, 19 – 21, 24 – 27 and 30.

Amend Claims 31 and 37 as set forth below.

COMPLETE LISTING OF ALL CLAIMS:

Claims 1 – 30 (canceled)

31. (currently amended) A pharmaceutical composition for the treatment of a malignant disease or condition in a mammal, said condition being selected from the group consisting of breast cancer and leukemia, the composition comprising a pharmaceutically acceptable excipient and a therapeutically effective dose of a compound of the formula



where **X** is S or O;

R_1 is, independently, H or lower alkyl of 1 to 6 carbons;

R_2 and **R_3** are, independently, H, lower alkyl of 1 to 6 carbons, F, Cl, Br, I, alkoxy of 1 to 6 carbons, or fluoroalkoxy of 1 to 6 carbons;

m is an integer 0 to 3;

o is an integer 0 to 4;

n is an integer 0-5;

Y is phenyl, naphthyl, or a heteroaryl group selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl; oxazolyl, thiazolyl, or imidazolyl; and

B is COOH, a pharmaceutically acceptable salt thereof, CON**R_6R_7** or COO**R_8** where **R_6** and **R_7**, independently, are hydrogen or an alkyl group of 1 to 6 carbons and **R_8** is alkyl of 1 to 6 carbons,

said composition being adapted to be used in combination with another chemotherapeutic agent effective for the treatment of the malignant disease or condition of the mammal where the composition in combination with the other chemotherapeutic agent shows synergistic effect.

C1

32. (previously added) A pharmaceutical composition in accordance with Claim 31 where the other chemotherapeutic agent is interferon.

33. (previously added) A pharmaceutical composition for the treatment of a malignant disease or condition in a mammal, said condition being selected from the group consisting of breast cancer and leukemia, the composition comprising a pharmaceutically acceptable excipient and a therapeutically effective dose of a compound of the formula



where $\mathbf{R_1}$ is H or methyl, $\mathbf{R_3}$ is H or methyl, and $\mathbf{R^*_8}$ is H, or lower alkyl of 1 to 3 carbons, or a pharmaceutically acceptable salt of said compound, said composition being adapted to be used in combination with another chemotherapeutic agent effective for the treatment of the malignant disease or condition of the mammal where the composition in combination with the other chemotherapeutic agent shows synergistic effect.

34. (previously added) A pharmaceutical composition in accordance with Claim 33 where the other chemotherapeutic agent is interferon.

35. (previously added) A pharmaceutical composition for the treatment of a malignant disease or condition in a mammal, said condition being selected from the group consisting of breast cancer and leukemia, the composition comprising a pharmaceutically acceptable excipient and a therapeutically effective dose of a

compound of the formula



where R_8 is H, alkyl of 1 to 3 carbons, or a pharmaceutically acceptable salt of said compound, said composition being adapted to be used in combination with another chemotherapeutic agent effective for the treatment of the malignant disease or condition of the mammal where the composition in combination with the other chemotherapeutic agent shows synergistic effect.

36. (previously added) A pharmaceutical composition in accordance with Claim 35 where the other chemotherapeutic agent is interferon.

37. (currently amended) A method of treating a malignant disease or condition in a mammal in need of such treatment, said condition being selected from the group consisting of breast cancer and leukemia, the method comprising the steps of:

administering to said mammal a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective dose of a compound of the formula



where **X** is S or O;

R_1 is, independently, H or lower alkyl of 1 to 6 carbons;

R_2 and R_3 are, independently, H, lower alkyl of 1 to 6 carbons, F, Cl, Br, I, alkoxy of 1 to 6 carbons, or fluoroalkoxy of 1 to 6 carbons;

m is an integer 0 to 3;

o is an integer 0 to 4;

n is an integer 0-5;

Y is phenyl, naphthyl, or a heteroaryl group selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl; oxazolyl, thiazolyl, or imidazolyl;

B is COOH, a pharmaceutically acceptable salt thereof, $CONR_6R_7$ or $COOR_8$ where R_6 and R_7, independently, are hydrogen or an alkyl group of 1 to 6 carbons and R_8 is alkyl of 1 to 6 carbons, and

co-administering to said mammal with said compound another chemotherapeutic agent effective for the treatment of the malignant disease or condition of the mammal where the composition in combination with the other chemotherapeutic agent shows synergistic effect.

38. (previously added) A method in accordance with Claim 37 where the chemotherapeutic agent is interferon.

39. (previously added) A method in accordance with Claim 38 where the chemotherapeutic agent is human recombinant interferon α, human recombinant interferon β, or human recombinant interferon γ.

40. (previously added) A method of treating a malignant disease or condition in a mammal in need of such treatment, said condition being selected from the group consisting of breast cancer and leukemia, the method comprising the steps of:

administering to said mammal a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective dose of a compound of the formula



where $\mathbf{R_1}$ is H or methyl, $\mathbf{R_3}$ is H or methyl, and $\mathbf{R^*_8}$ is H, or lower alkyl of 1 to 3 carbons, or a pharmaceutically acceptable salt of said compound, and

co-administering to said mammal with said compound another chemotherapeutic agent effective for the treatment of the malignant disease or condition of the mammal where the composition in combination with the other chemotherapeutic agent shows synergistic effect.

41. (previously added) A method in accordance with Claim 40 where the chemotherapeutic agent is interferon.

42. (previously added) A method in accordance with Claim 41 where the chemotherapeutic agent is human recombinant interferon α, human recombinant interferon β, or human recombinant interferon γ.

43. (previously added) A method of treating a malignant disease or condition in a mammal in need of such treatment, said condition being selected from the group consisting of breast cancer and leukemia, the method comprising the steps of:

administering to said mammal a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective dose of a compound of the formula



where $\mathbf{R_8}$ is H, alkyl of 1 to 3 carbons, or a pharmaceutically acceptable salt of said compound, and

co-administering to said mammal with said compound another chemotherapeutic agent effective for the treatment of the malignant disease or condition of the mammal where the composition in combination with the other chemotherapeutic agent shows synergistic effect.

44. (previously added) A method in accordance with Claim 43 where the chemotherapeutic agent is interferon.

45. (previously added) A method in accordance with Claim 44 where the chemotherapeutic agent is human recombinant interferon α, human recombinant interferon β, or human recombinant interferon γ.